Loading clinical trials...
Loading clinical trials...
Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease
Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.
This case -control observational prospective study will conducted on 40 patients with PD.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Effat abdelhady tony
Asyut, Egypt
Start Date
January 31, 2021
Primary Completion Date
July 1, 2021
Completion Date
January 1, 2022
Last Updated
June 2, 2021
80
ESTIMATED participants
SHMT1 polymorphism
GENETIC
Lead Sponsor
Assiut University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions